230 related articles for article (PubMed ID: 33394321)
41. Risk of Hepatocellular Carcinoma Remains High in Patients with HBV-Related Decompensated Cirrhosis and Long-Term Antiviral Therapy.
Zhu DM; Xie J; Ye CY; Qian MY; Xue Y
Can J Gastroenterol Hepatol; 2020; 2020():8871024. PubMed ID: 33381476
[TBL] [Abstract][Full Text] [Related]
42. Obesity and hepatocellular carcinoma in patients receiving entecavir for chronic hepatitis B.
Lee J; Yoo SH; Sohn W; Kim HW; Choi YS; Won JH; Heo JY; Park SJ; Park YM
Clin Mol Hepatol; 2016 Sep; 22(3):339-349. PubMed ID: 27729627
[TBL] [Abstract][Full Text] [Related]
43. Chronic Viral Hepatitis B and C Outweigh MASLD in the Associated Risk of Cirrhosis and HCC.
Lee MH; Chen YT; Huang YH; Lu SN; Yang TH; Huang JF; Yin SC; Yeh ML; Huang CF; Dai CY; Chuang WL; Yu ML; Yang HI; Chen HY; Chen CJ
Clin Gastroenterol Hepatol; 2024 Jun; 22(6):1275-1285.e2. PubMed ID: 38365094
[TBL] [Abstract][Full Text] [Related]
44. Association of central obesity with hepatocellular carcinoma in patients with chronic hepatitis B receiving antiviral therapy.
Fan R; Niu J; Ma H; Xie Q; Cheng J; Rao H; Dou X; Xie J; Zhao W; Peng J; Gao Z; Gao H; Chen X; Chen J; Li Q; Tang H; Zhang Z; Ren H; Cheng M; Liang X; Zhu C; Wei L; Jia J; Sun J; Hou J;
Aliment Pharmacol Ther; 2021 Aug; 54(3):329-338. PubMed ID: 34157146
[TBL] [Abstract][Full Text] [Related]
45. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B.
Kim GA; Lim YS; Han S; Choi J; Shim JH; Kim KM; Lee HC; Lee YS
Gut; 2018 May; 67(5):945-952. PubMed ID: 29055908
[TBL] [Abstract][Full Text] [Related]
46. Subcirrhotic liver stiffness by FibroScan correlates with lower risk of hepatocellular carcinoma in patients with HBV-related cirrhosis.
Jeon MY; Lee HW; Kim SU; Heo JY; Han S; Kim BK; Park JY; Kim DY; Ahn SH; Han KH
Hepatol Int; 2017 May; 11(3):268-276. PubMed ID: 28224351
[TBL] [Abstract][Full Text] [Related]
47. Prediction model for hepatocellular carcinoma risk in treatment-naive chronic hepatitis B patients receiving entecavir/tenofovir.
Yu JH; Suh YJ; Jin YJ; Heo NY; Jang JW; You CR; An HY; Lee JW
Eur J Gastroenterol Hepatol; 2019 Jul; 31(7):865-872. PubMed ID: 30694912
[TBL] [Abstract][Full Text] [Related]
48. Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B.
Kim WR; Loomba R; Berg T; Aguilar Schall RE; Yee LJ; Dinh PV; Flaherty JF; Martins EB; Therneau TM; Jacobson I; Fung S; Gurel S; Buti M; Marcellin P
Cancer; 2015 Oct; 121(20):3631-8. PubMed ID: 26177866
[TBL] [Abstract][Full Text] [Related]
49. Performance of risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B) score in classifying treatment eligibility under 2012 Asian Pacific Association for the Study of the Liver (APASL) guideline for chronic hepatitis B patients.
Chen TM; Chang CC; Huang PT; Wen CF; Lin CC
Aliment Pharmacol Ther; 2013 Jan; 37(2):243-51. PubMed ID: 23171385
[TBL] [Abstract][Full Text] [Related]
50. Natural History and Hepatocellular Carcinoma Risk in Untreated Chronic Hepatitis B Patients With Indeterminate Phase.
Huang DQ; Li X; Le MH; Le AK; Yeo YH; Trinh HN; Zhang J; Li J; Wong C; Wong C; Cheung RC; Yang HI; Nguyen MH
Clin Gastroenterol Hepatol; 2022 Aug; 20(8):1803-1812.e5. PubMed ID: 33465482
[TBL] [Abstract][Full Text] [Related]
51. Partial Virological Response after 2 Years of Entecavir Therapy Increases the Risk of Hepatocellular Carcinoma in Patients with Hepatitis B Virus-Associated Cirrhosis.
Shin SK; Yim HJ; Kim JH; Lee CU; Yeon JE; Suh SJ; Jung YK; Kim YS; Kim JH; Kwon OS
Gut Liver; 2021 May; 15(3):430-439. PubMed ID: 33115966
[TBL] [Abstract][Full Text] [Related]
52. Long-term lamivudine for chronic hepatitis B and cirrhosis: A real-life cohort study.
Su MH; Lu AL; Li SH; Zhong SH; Wang BJ; Wu XL; Mo YY; Liang P; Liu ZH; Xie R; He LX; Fu WD; Jiang JN
World J Gastroenterol; 2015 Dec; 21(46):13087-94. PubMed ID: 26673249
[TBL] [Abstract][Full Text] [Related]
53. Liver cirrhosis stages and the incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving antiviral therapy.
Shim JJ; Oh CH; Kim JW; Lee CK; Kim BH
Scand J Gastroenterol; 2017 Sep; 52(9):1029-1036. PubMed ID: 28562104
[TBL] [Abstract][Full Text] [Related]
54. Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection.
Chayanupatkul M; Omino R; Mittal S; Kramer JR; Richardson P; Thrift AP; El-Serag HB; Kanwal F
J Hepatol; 2017 Feb; 66(2):355-362. PubMed ID: 27693539
[TBL] [Abstract][Full Text] [Related]
55. Antiviral therapy and hepatocellular carcinoma risk in hepatitis B patients with cirrhosis.
Gao X; Yang HI; Trinh H; Jeong D; Li J; Zhang J; Le A; Hoang J; Nguyen P; Henry L; Nguyen MH
Eur J Gastroenterol Hepatol; 2020 Sep; 32(9):1207-1211. PubMed ID: 32129773
[TBL] [Abstract][Full Text] [Related]
56. Long-term effect of interferon therapy on incidence of cirrhosis and hepatocellular carcinoma in Thai patients with chronic hepatitis B.
Tangkijvanich P; Thong-ngam D; Mahachai V; Kladchareon N; Suwangool P; Kullavanijaya P
Southeast Asian J Trop Med Public Health; 2001 Sep; 32(3):452-8. PubMed ID: 11944697
[TBL] [Abstract][Full Text] [Related]
57. Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population.
Papatheodoridis GV; Sypsa V; Dalekos G; Yurdaydin C; van Boemmel F; Buti M; Goulis J; Calleja JL; Chi H; Manolakopoulos S; Loglio A; Siakavellas S; Gatselis N; Keskın O; Lehretz M; Savvidou S; de la Revilla J; Hansen BE; Kourikou A; Vlachogiannakos I; Galanis K; Idilman R; Colombo M; Esteban R; Janssen HLA; Berg T; Lampertico P
J Hepatol; 2018 Jun; 68(6):1129-1136. PubMed ID: 29427727
[TBL] [Abstract][Full Text] [Related]
58. Prognosis of Untreated Minimally Active Chronic Hepatitis B Patients in Comparison With Virological Responders by Antivirals.
Lee HW; Kim SU; Park JY; Baatarkhuu O; Kim DY; Ahn SH; Han KH; Kim BK
Clin Transl Gastroenterol; 2019 Jun; 10(6):e00036. PubMed ID: 31107725
[TBL] [Abstract][Full Text] [Related]
59. Disease Progression in Chronic Hepatitis B Patients under Long-Term Antiviral Therapy.
Moon JC; Kim SH; Kim IH; Lee CH; Kim SW; Lee SO; Lee ST; Kim DG
Gut Liver; 2015 May; 9(3):395-404. PubMed ID: 25473072
[TBL] [Abstract][Full Text] [Related]
60. [Study on the natural history of chronic hepatitis B].
Wu G; Zhou W; Zhao Y; Guo S; Wang Z; Zou S; Zhang Q; Ren H; Huang A; Zhang D
Zhonghua Gan Zang Bing Za Zhi; 2002 Feb; 10(1):46-8. PubMed ID: 11856503
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
